Background: Human papillomavirus (HPV) initiates cervical cancer, and continuous expression of
HPV oncogenes E6 and E7 is thought to be necessary to maintain malignant growth.
In general, these vaccines focus on the main
HPV oncogenes, E6 and E7.
In addition to
HPV oncogene expression, the researchers noted other distinct differences between the HPV - inactive and active classes of cervical cancers.
«Physicians managing cervical cancer patients should test for
HPV oncogene expression in these tumors and consider personalized treatment depending on HPV activity,» Banister said.
Unlike most cervical cancers — which are primarily driven by human papillomavirus — this subtype is initiated by the virus, but
HPV oncogene expression eventually disappears and does not sustain the cancer's growth.
Not exact matches
For example,
HPV - inactive tumors were 17 times more likely to contain disrupting TP53 gene mutations than
HPV - active cervical cancers, rendering unnecessary the expression of the
HPV E6
oncogene.